Remarkable outcomes showing substantial improvement in vitro pharmacological activity of naringin led the team to conclude to suggest potential use of a dry powder inhaler based on co‐spray dried naringin and leucine ‘as MAPK and NF‐κB inhibitors to treat lung intrinsic inflammation and prevent tissue damages in CF patients’.[22]. Here, NFKB1 is linked to cystic fibrosis.